The advanced analysis of immune parameters describing differentiation profile, activation and exhaustion of lymphocytes, monocytes and granulocytes of patients with moderate and severe/critical COVID-19 pneumonia was performed.

Cellular therapy develops rapidly throughout the world. The list of diseases of various etiologies that are treated with biomedical cellular products is constantly growing. The Center for Immunology and Allergology was opened in the The Institute of Biophysics and Cell Engineering of National Academy of Science of Belarus in 2021. Since that the developing of new biomedical cell products for the correction of immunopathological conditions was started in collaboration with the Belarusian State Medical University. The technologies for producing of biomedical cellular products based on cytokine-induced killer cells for the treatment of oncological diseases of the urogenital area, tolerogenic dendritic cells for the treatment of type 1 diabetes, and regulatory T lymphocytes for the treatment of sclerosis were developed.

Struma ovarii is a rare variant of the mature ovarian teratoma composed of more than 50% thyroid tissue. Thyroid type carcinoma can occur in 5% of struma ovarii. Given the rarity of this pathology, as well as the different clinical course, approaches to the treatment of this disease are controversial. The proposed approaches to treatment vary from ovarian resection to total hysterectomy with bilateral salpingo-oophorectomy and adjuvant therapy. We present here 6 case reports of thyroid type carcinoma in struma ovarii and outcome of patients treated in our clinic. All patients had pelvic surgery of different extent, followed by thyroidectomy and radioiodine therapy. The incidence of metastasis is 67% (4/6), 2 - intraperitoneal metas-tases, 2 - bone metastases. Among patients with metastases, 2 have reached a complete response, one with a good response continues treatment, one had progression. The follow-up period is 1 to 15 years (median 4 years). One patient with follicular carcinoma died of progression 8 years after diagnosis. The remaining patients are alive.